| 0.5576 0 (0%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Zosano Pharma Corporation is a biopharmaceutical enterprise, currently in the clinical development phase, focused on supplying therapeutic agents and other biologically active substances to patients afflicted with migraine using its specialized transdermal microneedle system. Their leading experimental compound, Qtrypta (M207), represents a distinct formulation of zolmitriptan, specifically intended for the swift management of acute migraine episodes. The company commenced operations in 2006 and maintains its principal offices in Fremont, California. Notably, Zosano Pharma Corporation initiated a voluntary Chapter 11 reorganization petition with the U.S. Bankruptcy Court for the District of Delaware on June 1, 2022.
Tue, 18 Oct 2022
Bankrupt Zosano sells intradermal delivery tech to Emergex Vaccines - Fierce Pharma
Fri, 17 Jun 2022
Zosano Pharma Corporation (ZSAN) Share Price Today | Zosano Pharma (ZSAN) Live NSE/BSE - Value Research
Tue, 07 Jun 2022
Zosano goes bankrupt after FDA rejects migraine drug delivery patch - Fierce Pharma
Thu, 02 Jun 2022
East Bay migraine patch developer files for bankruptcy - The Business Journals
Fri, 27 May 2022
Five Narrow Lane Made a Big Bet on Vinco Ventures (BBIG) Stock - InvestorPlace
Fri, 29 Apr 2022
Migraine patch developer Zosano Pharma suspends program, cutting more jobs - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|